Mar 31, 2022

Hannon Armstrong Q1 2022 Earnings Report

Reported strong NII growth, demonstrating the effectiveness of the dual-revenue business model despite macroeconomic challenges.

Key Takeaways

Hannon Armstrong reported a strong first quarter in 2022, with GAAP EPS of $0.51 and Distributable EPS of $0.52, a 21% year-over-year increase. The company closed $331 million in investments, and the portfolio grew 28% year-over-year to $3.7 billion. They also reaffirmed guidance for Distributable Earnings Per Share to grow at a compound annual rate of 10% to 13% from 2021 to 2024.

GAAP EPS was $0.51, compared to $0.61 for the same period in 2021.

Distributable EPS was $0.52, a 21% increase year-over-year.

Investments closed totaled $331 million, compared to $188 million in the same period in 2021.

Portfolio grew 28% year-over-year to $3.7 billion.

Total Revenue
$30.2M
Previous year: $25.1M
+20.5%
EPS
$0.52
Previous year: $0.43
+20.9%
Managed Assets
$9.04B
Previous year: $7.4B
+22.1%
Dividend per share
$0.375
Previous year: $0.35
+7.1%
Gross Profit
$58.5M
Previous year: $51.7M
+13.1%
Cash and Equivalents
$133M
Previous year: $232M
-42.6%
Total Assets
$4.22B
Previous year: $3.43B
+23.0%

Hannon Armstrong

Hannon Armstrong

Forward Guidance

The Company expects that annual distributable earnings per share will grow at a compounded annual rate of 10% to 13% from 2021 to 2024, relative to the 2020 baseline of $1.55 per share, which is equivalent to a 2024 midpoint of $2.40 per share. The Company also expects growth of annual dividends per share to be at a compounded annual rate of 5% to 8%.

Positive Outlook

  • Yield on its existing portfolio
  • Yield on incremental portfolio investments, inclusive of the Company’s existing pipeline
  • The volume and profitability of transactions
  • Amount, timing, and costs of debt and equity capital to fund new investments
  • Changes in costs and expenses reflective of the Company’s forecasted operations

Challenges Ahead

  • General interest rate and market environment
  • Ongoing and future impact of COVID-19
  • Speed and efficacy of vaccine distribution on economic conditions
  • The regulatory environment
  • The dynamics of the markets in which we operate